Pancreatic Cancer

>

Latest News

Safety findings highlight no severe adverse effects or dose-limiting toxicities with the rintatolimod combination in late-stage pancreatic cancer.
Rintatolimod/Durvalumab Dose Appears Tolerable in Pancreatic Cancer

April 30th 2024

Safety findings highlight no severe adverse effects or dose-limiting toxicities with the rintatolimod combination in late-stage pancreatic cancer.

The liquid biopsy combining miRNA and CA19-9 had the best validation rates for detecting pancreatic ductal adenocarcinoma.
miRNA Assay May Lead to Early Detection in PDAC

April 8th 2024

Higher CA19-9 levels appear to correlate with increased recurrence and mortality for specific patients with pancreatic cancer who undergo surgical resection.
Gene Test Modestly Improves CA19-9 Prognosis in Pancreatic Cancer Surgery

March 2nd 2024

Investigators are currently evaluating treatment with IMM-1-104 in pancreatic cancer and other disease types associated with the RAS pathway as part of a phase 1/2a study.
IMM-1-104 Earns FDA Fast Track Designation in Pancreatic Cancer

February 22nd 2024

A retrospective cohort study from the Trans-Atlantic Pancreatic Surgery Consortium determined a sustained OS rate with modified FOLFIRINIX in patients with pancreatic ductal adenocarcinoma.
mFOLFIRINOX Plus Clinical Staging Consideration May Improve OS in PDAC

February 16th 2024